A retrospective analysis of children until 18 years of age with congenital adrenal hyperplasia (CAH) treated with hydrocortisone modified-release hard capsules (Efmody®)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038319

Enrollment

Registered

2025-10-30

Start date

2024-03-05

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E25.00

Interventions

Group 1: Children and adolescents with congenital adrenal hyperplasia (CAH) who are receiving treatment with hydrocortisone and in case of salt wasting CAH also with fludrocortisone are included in th

Eligibility

Sex/Gender

All

Age

No minimum to 24 Years

Inclusion criteria

Inclusion criteria: CAH Therapy with hydrocortisone and if necessary with fludorcortisone continuous monitoring with 17-OHP saliva sampling during regular visits in the outpatient clinic

Exclusion criteria

Exclusion criteria: missing data before switch to Efmody therapy no treatment with hydrocortisone

Design outcomes

Primary

Measure	Time frame
Reduction of morning 17-hydroxyprogesterone	—

Secondary

Measure	Time frame
- no increase of adrenal crisis - improvement in treatment adherence - No increase in body mass index - Height development approaching parents' target range	—

Countries

Germany

Contacts

Public ContactUta Neumann

Charité Universitätsmedizin Berlin

uta.neumann@charite.de+4930666804

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jul 9, 2026